HistoSonics will use $102m in Series D funding to scale its operations and accelerate commercial growth in the US and internationally as it joins with leading institutions to develop multi-disciplinary histotripsy liver programs.
The Minneapolis, MN-based company received US Food and Drug Administration de novo clearance in October 2023 for its Edison Histotripsy...







